BAVIS_1170x120_1-20

Rob Davidson

CURE Pharmaceutical releases new drug delivery line

CURE Pharmaceutical releases new drug delivery line

OXNARD, Calif.  – CURE Pharmaceutical announces the expansion of its oral drug delivery product line creating CUREform which includes CUREfilm, one of the most advanced oral thin films on the market.  The new line adds CUREpods chewables and emulsions to meet increased demand for alternative dosage forms that can improve solubility and absorption. “Building on the

CURE Pharmaceutical and Canopy Growth to produce CBD oral thin films

CURE Pharmaceutical and Canopy Growth to produce CBD oral thin films

OXNARD, Calif. – CURE Pharmaceutical announced it is collaborating with Canopy Growth Corp. to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented CUREfilm technology for global distribution. This CUREfilm license gives Canopy a dosage form that is ideal for administering cannabinoids. “This collaboration builds on our licensing agreement with Canopy

CURE Pharmaceutical to manufacture pharmaceuticals using whole cannabis plant

CURE Pharmaceutical to manufacture pharmaceuticals using whole cannabis plant

OXNARD, Calif. – CURE Pharmaceutical Tuesday announced it has broadened its U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD). This license allows CURE to take advantage of its latest U.S. Patent No. 10,238,705 issuing this month for the extraction and purification of

CURE Pharmaceutical expands distribution of CUREfilm technology

CURE Pharmaceutical expands distribution of  CUREfilm technology

LOS ANGELES —  CURE Pharmaceutical today announced that it entered into a multi-year licensing agreement for the first time with leading international cannabis company Canopy Growth Corp. Under the terms of the agreement, Canopy Growth Corp will have an exclusive license to CURE’s patented, multi-layer oral thin film (OTF), CUREfilm technology for use with cannabis extracts and

Cure Pharmaceutical to acquire cannabinoid-based pipeline from Therapix Biosciences 

Cure Pharmaceutical to acquire cannabinoid-based pipeline from Therapix Biosciences 

OXNARD, Calif.  – Cure Pharmaceutical announced that it has signed a term sheet with Therapix Biosciences, a specialty, clinical-stage pharmaceutical company developing cannabinoid-based treatments, to acquire the non-pain assets of Therapix, subject to the completion of the related conditions. These assets include several clinical drug candidates as well as two pre-clinical drug candidates. Cure will issue shares